FRMD8 inhibits tumor metastasis in BRCA1-associated TNBC by negatively regulating tmTNF-α
Open Access
- 6 July 2025
- journal article
- research article
- Published by Springer Nature in Cellular & Molecular Biology Letters
- Vol. 30 (1) , 1-33
Abstract
Triple-negative breast cancer (TNBC), particularly in patients with metastasis, is associated with limited treatment options and shorter survival times. In this study, through library screening and animal experiments, we identified that the low expression of FERM domain-containing protein 8 (FRMD8) in breast cancer type 1 susceptibility protein (BRCA1)-mutant breast cancer cells (TNBC subtype), significantly enhances the metastatic potential of tumor cells to various organs. Further functional experiments revealed that FRMD8low inhibited the cleavage of tmTNF-α (transmembrane TNF-α) and promoted the expression of surface tmTNF-α. We also identified that the mechanism by which FRMD8 regulates tmTNF-α is related to the inhibition of inactive rhomboid protein 2 (iRHOM2) degradation, which acts mainly through the endocytic pathway. Furthermore, FRMD8low/iRHOM2low greatly facilitated the in vivo metastasis of TNBC. Finally, we found that combined treatment with paclitaxel and etanercept reversed the expression of FRMD8 and iRHOM2, concomitantly inhibiting the metastatic potential in vivo. This study explores how FRMD8 influences TNF-α processing and the metastatic behavior of breast cancer, providing insights into molecular dynamics that could guide future therapeutic strategies to improve outcomes in patients with breast cancer.Keywords
Funding Information
- National Natural Science Foundation of China (82303451)
This publication has 31 references indexed in Scilit:
- Cryo-EM reveals that iRhom2 restrains ADAM17 protease activity to control the release of growth factor and inflammatory signalsMolecular Cell, 2024
- Pathological mutations reveal the key role of the cytosolic iRhom2 N-terminus for phosphorylation-independent 14-3-3 interaction and ADAM17 binding, stability, and activityCellular and Molecular Life Sciences, 2024
- EGFR stimulation enables IL-6 trans-signalling via iRhom2-dependent ADAM17 activation in mammary epithelial cellsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2023
- Current and future burden of breast cancer: Global statistics for 2020 and 2040The Breast, 2022
- Effective suppression of triple negative breast cancer by paclitaxel nanoparticles conjugated with transmembrane TNF-α monoclonal antibodyInternational Journal of Pharmaceutics, 2022
- BRCA-1 mediated activation of NF-κβ and its pro-inflammatory network drives tumorigenesis in benign breast disease patientsHuman Gene, 2022
- Carboxyl group-modified α-lactalbumin induces TNF-α-mediated apoptosis in leukemia and breast cancer cells through the NOX4/p38 MAPK/PP2A axisInternational Journal of Biological Macromolecules, 2021
- The dual role of tumor necrosis factor-alpha (TNF-α) in breast cancer: molecular insights and therapeutic approachesCellular Oncology, 2020
- Status update on iRhom and ADAM17: It's still complicatedBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2019
- Therapeutic potential of ADAM17 modulation in gastric cancer through regulation of the EGFR and TNF-α signalling pathwaysMolecular and Cellular Biochemistry, 2016